These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23065826)

  • 1. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.
    Gurdasani D; Sjouke B; Tsimikas S; Hovingh GK; Luben RN; Wainwright NW; Pomilla C; Wareham NJ; Khaw KT; Boekholdt SM; Sandhu MS
    Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3058-65. PubMed ID: 23065826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study.
    van Wijk DF; Boekholdt SM; Wareham NJ; Ahmadi-Abhari S; Kastelein JJ; Stroes ES; Khaw KT
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2888-94. PubMed ID: 24072695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity C-reactive Protein, Lipoprotein(a) and Homocysteine are Risk Factors for Coronary Artery Disease in Japanese Patients with Peripheral Arterial Disease.
    Kumakura H; Fujita K; Kanai H; Araki Y; Hojo Y; Kasama S; Iwasaki T; Ichikawa S; Nakashima K; Minami K
    J Atheroscler Thromb; 2015; 22(4):344-54. PubMed ID: 25296963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study.
    Zheng KH; Arsenault BJ; Kaiser Y; Khaw KT; Wareham NJ; Stroes ESG; Boekholdt SM
    J Am Heart Assoc; 2019 Aug; 8(16):e013020. PubMed ID: 31407609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease.
    Golledge J; Rowbotham S; Velu R; Quigley F; Jenkins J; Bourke M; Bourke B; Thanigaimani S; Chan DC; Watts GF
    J Am Heart Assoc; 2020 Mar; 9(6):e015355. PubMed ID: 32172653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.
    Volis I; Saliba W; Jaffe R; Eitan A; Zafrir B
    Am J Cardiol; 2020 Aug; 128():28-34. PubMed ID: 32650921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease.
    Sanchez Muñoz-Torrero JF; Rico-Martín S; Álvarez LR; Aguilar E; Alcalá JN; Monreal M;
    Atherosclerosis; 2018 Sep; 276():10-14. PubMed ID: 30006322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
    Tsimikas S; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Sandhu MS; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Boekholdt SM
    J Am Coll Cardiol; 2010 Sep; 56(12):946-55. PubMed ID: 20828647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
    van Capelleveen JC; Bernelot Moens SJ; Yang X; Kastelein JJP; Wareham NJ; Zwinderman AH; Stroes ESG; Witztum JL; Hovingh GK; Khaw KT; Boekholdt SM; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1206-1212. PubMed ID: 28473441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis.
    Forbang NI; Criqui MH; Allison MA; Ix JH; Steffen BT; Cushman M; Tsai MY
    J Vasc Surg; 2016 Feb; 63(2):453-8. PubMed ID: 26518096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
    Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study.
    Stoekenbroek RM; Boekholdt SM; Luben R; Hovingh GK; Zwinderman AH; Wareham NJ; Khaw KT; Peters RJ
    Eur Heart J; 2016 Mar; 37(11):880-9. PubMed ID: 26681771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease.
    Liu HH; Cao YX; Jin JL; Zhang HW; Hua Q; Li YF; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Hong LF; Li JJ
    Heart; 2020 Aug; 106(16):1228-1235. PubMed ID: 32381650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of lipoprotein(a) for assessing the prevalence and severity of lower-extremity peripheral artery disease among patients with acute coronary syndrome.
    Okubo R; Nakanishi R; Oka Y; Kojima Y; Matsumoto S; Aikawa H; Noike R; Yabe T; Amano H; Toda M; Ikeda T
    Heart Vessels; 2023 Feb; 38(2):177-184. PubMed ID: 36068447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidation-specific biomarkers and risk of peripheral artery disease.
    Bertoia ML; Pai JK; Lee JH; Taleb A; Joosten MM; Mittleman MA; Yang X; Witztum JL; Rimm EB; Tsimikas S; Mukamal KJ
    J Am Coll Cardiol; 2013 May; 61(21):2169-79. PubMed ID: 23541965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
    El Harchaoui K; van der Steeg WA; Stroes ES; Kuivenhoven JA; Otvos JD; Wareham NJ; Hutten BA; Kastelein JJ; Khaw KT; Boekholdt SM
    J Am Coll Cardiol; 2007 Feb; 49(5):547-53. PubMed ID: 17276177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study.
    Aronis KN; Zhao D; Hoogeveen RC; Alonso A; Ballantyne CM; Guallar E; Jones SR; Martin SS; Nazarian S; Steffen BT; Virani SS; Michos ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Biomarker Discovery for Risk of Peripheral Artery Disease Compared With Coronary Artery Disease: Lipoprotein and Metabolite Profiling of 31 657 Individuals From 5 Prospective Cohorts.
    Tikkanen E; Jägerroos V; Holmes MV; Sattar N; Ala-Korpela M; Jousilahti P; Lundqvist A; Perola M; Salomaa V; Würtz P
    J Am Heart Assoc; 2021 Dec; 10(23):e021995. PubMed ID: 34845932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.